The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56+ Acute Monoblastic LeukaemiaAlessia Casolaro, Rachele Alzani, Alice Pezzoni et al.|PLoS ONE|2013Cited by 34
A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trialGerardo Rosati, Roberto Labianca, Chiara Alessandra Cella et al.|Gastric Cancer|2022Cited by 4
PLK1 expression in AML-NS8 cells and activity of PLK1 inhibitor NMS-937 <i>in vitro</i> and <i>in vivo</i>.Alessia Casolaro, Rachele Alzani, Josée Golay et al.|Figshare|2015Cited by 0